Borealis appoints IMCD as Bormed™ healthcare portfolio distributor
The distribution agreement will take effect as of October 1, 2021. The new agreement applies to Bormed™ portfolio of innovative polyolefin grades for healthcare. Complementary Borealis and IMCD product portfolios will enable even more choice in polymers.
Borealis announces that it has selected IMCD, a global leader in the distribution of specialty chemicals and ingredients, as its new European distributor of its dedicated grade range of Bormed™ polyolefins for healthcare.
The distribution agreement covers most of Europe (with the exception of Switzerland and the South-Eastern countries) and takes effect as of 1 October 2021. It applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices.
As a distributor with a strong presence in medical and healthcare applications, IMCD is the ideal partner for Borealis customers in Europe thanks to its broad technical expertise and dedicated medical application team. The extensive IMCD polymers range complements the Borealis Bormed portfolio, opening a range of new possibilities.
IMCD was selected from a broad field of potential distributors following a rigorous screening process.
“We are pleased to have found in IMCD a partner sharing the core Bormed values of service, commitment and conformance,” said John Webster, Borealis Head of Sales Advanced Products.
“What also unites us is our dedication to providing best-in-class service to all of our healthcare customers, both direct and indirect, by way of more intensive and efficient value chain collaboration. We are confident that this new agreement will significantly boost our presence in this increasingly important sector.”
In line with its commitment to service as the foundation of successful industry co-operation, Borealis and IMCD will together ensure a seamless distribution transition for their customers, who can continue to count on security of supply as well as the ready assistance of experienced technical and sales teams.
Olivier Champault, Director of IMCD Business Group Advanced Materials said: “We are delighted to be selected as the new partner for Borealis in their healthcare business. This partnership is completely aligned with our strategy to further expand and strengthen our presence in the medical and healthcare segment in Europe.
With our dedicated experts in medical and healthcare applications, our well-established distribution network, and our board product offering, we are fully committed to accelerate growth and to support our customers in their developments and innovations.”
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News CPHI Pharma Awards 2024: Meet the winners from the CPHI Celebration
This year we had a lot to celebrate, the 35th Anniversary of CPHI, and our esteemed award winners, of which we included two additional categories this year, the Future Leader award, and Woman of the Year award. -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance